Los puntos clave no están disponibles para este artículo en este momento.
Successful development of future targeted therapies will require the flexibility to rapidly evaluate combination regimens involving new targeted agents in a single development program. The FDA has therefore developed draft guidance on drug co-development.
Woodcock et al. (Wed,) studied this question.